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Is Ischemia Dead
After STICH?*
Raymond J. Gibbons, MD, Todd D. Miller, MD
Rochester, Minnesota
The STICH (Surgical Treatment for IsChemic Heart Failure)
(1) study in this issue of the Journal was a National Heart,
ung, and Blood Institute–sponsored trial that compared
utcomes of patients with coronary artery disease (CAD)
nd left ventricular ejection fraction (LVEF) 35% ran-
omized to medical therapy alone versus medical therapy
lus coronary artery bypass grafting (CABG). In 2 previous
ublications (2,3), the investigators reported that: 1) there
as no significant difference in death from any cause
etween treatment arms; and that 2) the presence of
yocardial viability did not identify patients with better
urvival with CABG. The current issue includes a substudy
xamining the prognostic significance of stress-induced
schemia in patients enrolled in STICH who had exercise or
asodilator single-photon emission computed tomography
SPECT) and/or dobutamine echocardiographic studies
hat were considered suitable for assessment of ischemia.
he investigators report that stress-induced ischemia failed
o identify: 1) patients with a worse prognosis; or 2) patients
ho were more likely to benefit from CABG, which is
onsistent with the previous analysis of viability. These
TICH publications challenge existing clinical dogma.
See page 1860
The clinical emphasis on stress-induced ischemia extends
back more than 30 years. Landmark observational studies
suggested that patients with ischemia were more likely to
have severe CAD (4) and that patients with ischemia had
higher rates of subsequent cardiac events than patients with
similar anatomic CAD who did not have inducible ischemia
(5). Tests for ischemia were included in clinical trials and
associated registries. Because these trials and registries
predated the widespread use of stress cardiac imaging, they
used the exercise electrocardiogram and ambulatory electro-
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(Coronary Artery Surgery Study) registry, the benefit of
CABG was greatest in patients who had 1 mm of
ST-segment depression at stage 1 or less (6). In the ECSS
(European Coronary Surgery Study), patients with 3-vessel
CAD or 2-vessel CAD including proximal left anterior
descending disease had improved survival with CABG
if they had1.5 mm ST-segment depression on a treadmill
test (7). The ACIP (Asymptomatic Cardiac Ischemia Pilot)
trial used ambulatory monitoring to detect ischemia.
Patients randomized to revascularization rather than to a
symptom-guided or ischemia-guided program of medical
therapy had improved outcomes (8).
These results were reflected in clinical training and
practice. Stress cardiac imaging with SPECT and echocar-
diography was used in multiple observational studies that
demonstrated worse patient outcomes in the presence of
stress-induced ischemia. Multiple clinical practice guide-
lines incorporated this concept to identify patients who
were candidates for angiography and those with certain
anatomic findings who were more likely to benefit from
revascularization (9 –12).
More recent randomized trials comparing treatment
strategies for CAD have required the presence of ischemia
for entry. The COURAGE (Clinical Outcomes Using
Revascularization and Aggressive DruG Evaluation) trial
randomized patients with class I to III angina, many with
objective evidence of ischemia, to percutaneous coronary
intervention (PCI) plus intensive medical therapy or inten-
sive medical therapy alone, and found no difference in
subsequent hard events (13). Likewise, the BARI 2D
(Bypass Angioplasty Revascularization Investigation 2 Di-
abetes) trial enrolled diabetic patients who had mild angina
or were asymptomatic with objective evidence of ischemia to
revascularization or medical therapy alone, and found no
advantage of revascularization (14). Two recent trials that
compared PCI and CABG as revascularization strategies in
patients with multivessel CAD required symptomatic
and/or objective evidence of ischemia for eligibility (15,16).
Nuclear cardiology substudies from COURAGE yielded
conflicting results. On the basis of serial imaging and
objective core laboratory quantitative measurements, PCI
plus optimal medical therapy reduced stress-induced isch-
emia more frequently than optimal medical therapy alone
(17). Patients with severe ischemia at baseline, and subse-
quent reduction in ischemia on follow-up testing, had lower
subsequent cardiac event rates. However, this post-
randomization analysis could be only hypothesis generating.
In a second substudy from the same trial, using subjective
SPECT assessment by the site investigators, baseline isch-
emia did not predict adverse events or a benefit in outcome
if treated by PCI (18). The nuclear cardiology substudy
from the BARI-2D trial reported that patients randomized
to revascularization were more likely to have no ischemia on
their 1-year SPECT studies (59% vs. 49%, p  0.001) (19).
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years were significantly related to LVEF, percent of abnor-
mal myocardium, and percent of scarred myocardium, but
not to percent of ischemic myocardium.
The applicability of any previous data to the patient
opulation enrolled in STICH is questionable. Patients
ith severely abnormal LVEF were generally excluded from
revious trials and registries; in contrast, entry into STICH
equired an LVEF 35%. Previous data were based on
patients with chest pain; in contrast, patients with class III
or greater angina were excluded from STICH. Few, if any,
of the patients enrolled in previous trials and registries were
treated with implantable cardioverter defibrillators (ICDs);
many of these studies predated the availability of ICDs. In
contrast, 22% of the patients enrolled in this STICH
substudy were treated with ICDs. STICH followed a
complex protocol that included the potential randomization
of suitable patients to surgical left ventricular reconstruc-
tion, which likely introduced selection bias. Enrollment in
the trial proved to be difficult, and not all patients received
the ischemia testing that was originally planned.
As acknowledged by the authors, this substudy had a
number of limitations. Most important, it was underpow-
ered. The power calculations were based on the overall
STICH population, not on this substudy. The 95% confi-
dence limits for patients with ischemia included a reduction
of 23% in total mortality, 25% in cardiovascular mortality,
and 15% in the combined endpoint of all-cause mortality
and cardiovascular hospitalization.
Multiple factors may have further attenuated the impact
of ischemia. Older observational data showed that the next
cardiac event in patients with severely reduced LVEF is
usually cardiac death (20). The CASS registry reported that
the mortality benefit from CABG in patients with abnormal
LVEF was primarily related to a reduction in sudden cardiac
death (21). The authors have published a preliminary
analysis suggesting that these older data were replicated
within the STICH trial, in which CABG reduced the rate
of sudden cardiac death and fatal myocardial infarction (22).
ICDs may have effectively terminated potentially lethal
arrhythmias in a portion of the 22% of patients who had
ICDs. The rates of baseline evidence-based medical therapy
in STICH were high (80% to 90%). More than one quarter
of the population had single-vessel CAD. The prognostic
implications of ischemia (peri-infarction) in these patients
may be different from patients with multivessel CAD.
Patients who underwent ischemia testing were different
from the remainder of the STICH population with respect
to race, LVEF, volumes, and ICD use.
The nuclear and echocardiographic measures of ischemia
were not identical. The nuclear summed difference score
(SDS) reflects both the extent and the severity of ischemia.
The ischemia criterion of SDS 4 translates into a “% of
ischemic myocardium” of 6% of the left ventricle. In
contrast, the echocardiographic assessment considered only
the extent of ischemia. The ischemia criterion of 2 Tsegments translates into a “% of ischemic myocardium” of
12% of the left ventricle. We are skeptical that these 2
criteria to detect the presence of ischemia are equivalent.
The authors do not provide any evidence to support these
thresholds.
Does the analysis of percent ischemic myocardium as a
continuous variable address this issue? In the 256 patients
with ischemia, mean percent ischemic myocardium was
18  11%. The distribution of this variable was likely
different in patients studied by nuclear and echocardio-
graphic techniques. All of the patients with values between
6% and 11% had to be studied by SPECT. Although 199
patients had ischemic myocardium 10%, all 129 patients
studied by echocardiographic techniques (by definition) had
to be in this group, leaving only 70 patients studied by
nuclear techniques with moderate-to-severe ischemia (p 
.0001 for nuclear vs. echocardiography by 2  2 chi-
square). Although 75 patients had ischemic myocardium
20%, few of these patients were likely studied by SPECT,
because an SDS 14 is rare in our experience, especially in
the setting of LVEF 35%. Although separate (and nega-
tive) analyses were performed for SPECT and echocardi-
ography, the nuclear analysis was severely underpowered, given
the small number of patients studied by nuclear techniques
with moderate to severe ischemia. In the STICH viability
substudy (2), SPECT (p  0.007) but not echocardiography
(p  0.277) was significantly associated with mortality on
univariate analysis (Supplemental Table 8 [2]), providing
dditional evidence that these 2 imaging techniques perform
ifferently in these patients. Both the nuclear images and
chocardiograms were interpreted subjectively. The repro-
ucibility of the echocardiographic assessment of ischemia
ith LVEF 35% has not been reported; limited available
uclear data are not reassuring (23).
What are the clinical implications of this STICH sub-
tudy for the management of patients with CAD and LVEF
35% (but not left main CAD or class III or greater
ngina) by the evidence-based clinician? Although this
ubstudy does not provide any evidence to support a role for
tress-induced ischemia in identifying patients who are
ore likely to benefit from CABG, given its limited power,
he absence of evidence of benefit must not be interpreted as
vidence of lack of benefit. Experienced clinicians should
ontinue to practice individualized medicine and to identify
atients with moderate-severe ischemia and matching se-
ere anatomic CAD, who may be more likely to benefit
rom revascularization if they can be successfully revascular-
zed at low risk. These results emphasize the importance of
hared decision making. Patients and physicians must bal-
nce the modest benefit on patient outcomes demonstrated
n the overall STICH trial with individual patient surgical
isk, best assessed by the Society of Thoracic Surgeons risk
core. These results, as well as those of other recent trials,
ertainly argue for continuing research to clarify the role of
schemia in the optimal management of patients with CAD.
his effort should include randomized trials, such as the
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sponsored ISCHEMIA (International Study of Compara-
tive Health Effectiveness with Medical and Invasive Ap-
proaches) trial, as well as comparative effectiveness studies
using existing registries. In the meantime, responsible cli-
nicians must be cautious in applying the existing clinical
dogma that stress-induced ischemia or viability provides
evidence of greater potential benefit from revascularization
in patients with depressed LVEF without severe angina.
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